At the end of May, myeloma researchers would have flocked to Chicago for the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) to learn the latest about myeloma research, along with thousands of other subspecialty cancer investigators. Instead, the conference was held virtually and we ‘attended’ remote.

Here are some interesting information:

• CAR T-Cell therapy: JNJ-4528 (page 22)
   
• Bi-specific BCMA antibody: Teclistanab (page 23)
   
• KRd vs VRd for initial therapy of newly-diagnosed myeloma (page 42)
   
• DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with Vd in relapsed/refractory myeloma (page 44)
   
• Myeloma worldwide vaccination rates and impact on infection, hospitalization and death (page 42)
   
• Myeloma patient-reported vaccination and antibiotic use (page 43)
   
• Raje Relays Recent Developments in Multiple Myeloma